Blockchain Technology in Clinical Trials

Main Article Content

Uli Broedl

Abstract

Session Description: “The rights, safety, and well-being of subjects participating in clinical trials are most important considerations [E6 (R2) Good Clinical Practice]”. The objective of this session is to discuss the value proposition of blockchain technology for various stakeholders in the complex clinical trial ecosystem, barriers that limit the adoption of blockchain technology in clinical trials, and opportunities to overcome those challenges.


Thank you , Bronze Sponsor, Boehringer Ingelheim

Downloads

Download data is not yet available.

Article Details

How to Cite
Broedl, U. (2018). Blockchain Technology in Clinical Trials. Blockchain in Healthcare Today. Retrieved from https://blockchainhealthcaretoday.com/index.php/journal/article/view/79
Section
Track: Blockchain
Author Biography

Uli Broedl, Boehringer Ingelheim, Canada, Medical Director and Vice President of Medical and Regulatory Affairs

https://boehringer-ingelheim.ca/en

Dr. Uli Broedl, MD, is Medical Director and Vice President of Medical and Regulatory Affairs at Boehringer Ingelheim Canada since January 2017. He is the medical representative of the company’s executive leadership team and oversees all aspects of clinical operations, clinical development, medical affairs, regulatory affairs, drug safety and clinical quality management. Dr. Broedl is passionate about fostering innovation
and new disruptive technologies that hold promise to improve patient care (e.g., blockchain technology in healthcare).

After having joined Boehringer Ingelheim in 2009 as global Deputy Therapeutic Area Head Metabolism, Dr. Broedl was responsible for building a Late Clinical Development team that drove the global registrations of various glucose-lowering medications in patients with type 2 diabetes mellitus.

Dr. Broedl is adjunct Professor of Medicine at the University of Munich, Germany, and holds a Doctorate of Medicine degree from the University of Munich. He completed a Postdoctoral Fellowship in Dr. Daniel J. Rader ́s lab, Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, and completed his

training in Internal Medicine, Endocrinology and Metabolism at the Medical Center of the University of Munich.